ID: ALA4096060

Max Phase: Preclinical

Molecular Formula: C27H23FN4O4

Molecular Weight: 486.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(/C=C/c1ccc(CCNC(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)cc1)NO

Standard InChI:  InChI=1S/C27H23FN4O4/c28-23-11-9-19(16-24-20-3-1-2-4-21(20)27(35)31-30-24)15-22(23)26(34)29-14-13-18-7-5-17(6-8-18)10-12-25(33)32-36/h1-12,15,36H,13-14,16H2,(H,29,34)(H,31,35)(H,32,33)/b12-10+

Standard InChI Key:  LXCLGXFJSUMMJY-ZRDIBKRKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 486.50

Molecular Weight (Monoisotopic): 486.1703

AlogP: 3.14

#Rotatable Bonds: 8

Polar Surface Area: 124.18

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.41

CX Basic pKa:

CX LogP: 3.25

CX LogD: 3.25

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.17

Np Likeness Score: -1.00

References

1. Yuan Z, Chen S, Sun Q, Wang N, Li D, Miao S, Gao C, Chen Y, Tan C, Jiang Y..  (2017)  Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.,  25  (15): [PMID:28601509] [10.1016/j.bmc.2017.05.058]

Source

Source(1):

• Scientific Literature